. Author manuscript; available in PMC: 2009 Nov 30.

Published in final edited form as: Expert Rev Anticancer Ther. 2009 Jan;9(1):51–60. doi: 10.1586/14737140.9.1.51

Table 3.

Average annual rates of noninvasive breast cancer by treatment group and type of noninvasive disease in the NSABP STAR trial.

Type of noninvasive disease	Events (n)		Rate per 1000 individuals			Risk ratio^*	95% confidence interval
Type of noninvasive disease	Tamoxifen	Raloxifene	Tamoxifen	Raloxifene	Difference^‡	Risk ratio^*	95% confidence interval
DCIS	30	44	0.79	1.16	−0.37	1.46	0.90–2.41
LCIS	21	29	0.56	0.76	−0.20	1.37	0.76–2.54
Mixed	6	7	0.16	0.18	−0.02	1.16	0.33–4.18
Total	57	80	1.51	2.11	−0.60	1.40	0.98–2.02

Risk ratio for women in the raloxifene group compared to women in the tamoxifen group.

^‡

Rate in the tamoxifen group minus rate in the raloxifene group.

DCIS: Ductal carcinoma in situ; LCIS: Lobular carcinoma in situ; NSASP: National Surgical Adjuvant Breast and Bowel Project; STAR: Study of Tamoxifen and Raloxifene. Reproduced with permission from [25].